Mydriasis in a Parkinson's disease patient on low-dose carbidopa/levodopa

被引：0
|
作者：
Burdick, D. J.
Griffith, A.
Cole, A.
Sia, C. M.
Agarwal, P.
机构：
来源：
MOVEMENT DISORDERS | 2013年 / 28卷
关键词：
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
613
引用
收藏
页码：S218 / S218
页数：1
相关论文
共 50 条
  • [41] Continuous intestinal infusion of levodopa/carbidopa in advanced Parkinson's disease: efficacy, safety and patient selection
    Abbruzzese, Giovanni
    Barone, Paolo
    Bonuccelli, Ubaldo
    Lopiano, Leonardo
    Antonini, Angelo
    FUNCTIONAL NEUROLOGY, 2012, 27 (03) : 147 - 154
  • [42] Levodopa/carbidopa/entacaponePisa syndrome (first report with entacapone) in a patient with Parkinson's disease: case report
    Reactions Weekly, 2009, 1239 (1) : 20 - 21
  • [43] Optimization of use of levodopa in Parkinson's disease:: role of levodopa-carbidopa-entacapone combination
    Castro, A
    Valldeoriola, F
    Linazasoro, G
    Rodriguez-Oroz, MC
    Stochi, F
    Marín, C
    Rodríguez, M
    Vaamonde, J
    Jenner, P
    Alvarez, L
    Pavón, N
    Macías, R
    Luquín, MR
    Hernández, B
    Grandas, F
    Giménez-Roldán, S
    Tolosa, ES
    Obeso, EJ
    NEUROLOGIA, 2005, 20 (04): : 180 - 188
  • [44] Pharmacokinetics of levodopa/benserazide versus levodopa/carbidopa in healthy subjects and patients with Parkinson's disease
    Iwaki, Hirotaka
    Nishikawa, Noriko
    Nagai, Masahiro
    Tsujii, Tomoaki
    Yabe, Hayato
    Kubo, Madoka
    Ieiri, Ichiro
    Nomoto, Masahiro
    NEUROLOGY AND CLINICAL NEUROSCIENCE, 2015, 3 (02): : 68 - 73
  • [45] Clinical Improvement and drastic reduction of Equivalent Dose of Levodopa (LEDD) in an Advanced Parkinson's Disease Patient after Levodopa/Entacapone/Carbidopa Intestinal Gel (LECIG) Treatment
    Tabar Comellas, G.
    Morales Casado, M. I.
    Segundo-Rodriguez, J. C.
    Lopez Ariztegui, N.
    MOVEMENT DISORDERS, 2023, 38 : S628 - S629
  • [46] Effect of carbidopa, entacapone and levodopa at bed time on sleep quality in Parkinson's disease compared to levodopa and carbidopa-CR
    Ma, H. I.
    Baik, J. S.
    Kang, S. Y.
    Kim, J. W.
    Kim, Y. J.
    MOVEMENT DISORDERS, 2012, 27 : S219 - S219
  • [47] Effects of One-Day Application of Levodopa/Carbidopa/Entacapone versus Levodopa/Carbidopa/Opicapone in Parkinson's Disease Patients
    Mueller, Thomas
    Schlegel, Eugen
    Zingler, Stephanie
    Thiede, Hans Michael
    CELLS, 2022, 11 (09)
  • [48] PHARMACOKINETICS OF INHALED LEVODOPA (ADMINISTERED WITH ORAL CARBIDOPA) AND ORAL CARBIDOPA/LEVODOPA IN SUBJECTS WITH PARKINSON'S DISEASE UNDER FED CONDITIONS
    Safirstein, B. E.
    Ellenbogen, A.
    Zhao, P.
    Henney, H. R., III
    Kegler-Ebo, D. M.
    Oh, C.
    PARKINSONISM & RELATED DISORDERS, 2020, 79 : E68 - E68
  • [49] CARBIDOPA-LEVODOPA COMBINATION IN TREATMENT OF PARKINSON DISEASE
    BOUNDS, JA
    HUNT, GM
    WESTERN JOURNAL OF MEDICINE, 1977, 127 (02): : 135 - 136
  • [50] LEVODOPA, CARBIDOPA, AND PYRIDOXINE IN PARKINSON DISEASE - METABOLIC INTERACTIONS
    MARS, H
    ARCHIVES OF NEUROLOGY, 1974, 30 (06) : 444 - 447
12345